Kura Oncology to Participate in Two Investor Conferences in November
Globe Newswire•13/11/2026•12:33 ET
1
Key Highlights
- ➤Kura Oncology management to present at two investor conferences November 17-18, 2026
- ➤UBS Global Biopharma London Conference presentation scheduled for November 17
- ➤Jefferies Global Healthcare Conference presentation scheduled for November 18
- ➤Kura continues commercializing FDA-approved oral menin inhibitor KOMZIFTI (ziftomenib)
SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:
UBS Global Biopharma London Conference November 17, 2026 1:20 p.m. GMT/ 8:20 a.m. ET / 5:20 a.m. PT
Get started
Create a free account to read the full story.